Ginsenoside Rb1 and berberine synergistically protect against type 2 diabetes mellitus via GDF15/HAMP pathway throughout the liver lobules: Insights from spatial transcriptomics analysis

Type 2 diabetes mellitus (T2DM) is a significant public health issue with high morbidity and mortality. Ginsenoside Rb1 (Rb1) and berberine (BBR), the main bioactive compounds of Panax ginseng and Coptis chinensis, respectively, are known for their hypoglycemic effects. Nevertheless, the synergistic...

Full description

Saved in:
Bibliographic Details
Main Authors: Rongfang Guo, Shuying Zhang, Anyao Li, Ping Zhang, Xin Peng, Xiaoyan Lu, Xiaohui Fan
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:Pharmacological Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661825001367
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849713750348660736
author Rongfang Guo
Shuying Zhang
Anyao Li
Ping Zhang
Xin Peng
Xiaoyan Lu
Xiaohui Fan
author_facet Rongfang Guo
Shuying Zhang
Anyao Li
Ping Zhang
Xin Peng
Xiaoyan Lu
Xiaohui Fan
author_sort Rongfang Guo
collection DOAJ
description Type 2 diabetes mellitus (T2DM) is a significant public health issue with high morbidity and mortality. Ginsenoside Rb1 (Rb1) and berberine (BBR), the main bioactive compounds of Panax ginseng and Coptis chinensis, respectively, are known for their hypoglycemic effects. Nevertheless, the synergistic effects and underlying mechanism of Rb1 and BBR on T2DM remain unclear. In this study, we utilized a leptin receptor-deficient (db/db) mouse model to investigate the protective effects of their combination treatment. Our findings demonstrated that the combined use of Rb1 and BBR at a 1:4 ratio had more pronounced effects than the first-line anti-diabetic drug metformin on reducing the weight ratio of white adipose tissue, ameliorating insulin resistance, and improving glucose and lipid metabolism. Using spatial transcriptomics, we revealed that metformin treatment improved gluconeogenesis and lipogenesis only in the periportal zone, while the combination treatment induced improvements throughout the liver lobule, with distinct key targets across different zones, thus underscoring a more comprehensive modulation of hepatic metabolism. This may be the key reason why this combination therapy demonstrated superior protective effects against T2DM. Additionally, the reversed expression of the key callback gene hepcidin (HAMP) and its regulator growth differentiation factor 15 (GDF15) following the combination therapy across all zones, along with validation experiments, further suggested that GDF15/HAMP pathway might be a key mechanism underlying the beneficial effects of Rb1 and BBR against T2DM. This study also indicates a path toward innovative drug cocktails for treating T2DM, offering a holistic approach to regulate the entire liver lobule metabolism.
format Article
id doaj-art-4a6fb16fbb5c4222b04ec00bbd397775
institution DOAJ
issn 1096-1186
language English
publishDate 2025-05-01
publisher Elsevier
record_format Article
series Pharmacological Research
spelling doaj-art-4a6fb16fbb5c4222b04ec00bbd3977752025-08-20T03:13:52ZengElsevierPharmacological Research1096-11862025-05-0121510771110.1016/j.phrs.2025.107711Ginsenoside Rb1 and berberine synergistically protect against type 2 diabetes mellitus via GDF15/HAMP pathway throughout the liver lobules: Insights from spatial transcriptomics analysisRongfang Guo0Shuying Zhang1Anyao Li2Ping Zhang3Xin Peng4Xiaoyan Lu5Xiaohui Fan6Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaPharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; School of Clinical Medicine, Shanghai University of Medicine & Health Sciences, Shanghai 201318, ChinaPharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaPharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaThe Joint‑Laboratory of Clinical Multi‑Omics Research between Zhejiang University and Ningbo Municipal Hospital of TCM, Ningbo Municipal Hospital of TCM, Ningbo 315010, ChinaPharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; State Key Laboratory of Chinese Medicine Modernization, Innovation Center of Yangtze River Delta, Zhejiang University, Jiaxing 314100, China; Jinhua Institute of Zhejiang University, Jinhua 321299, China; Corresponding authors at: Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; State Key Laboratory of Chinese Medicine Modernization, Innovation Center of Yangtze River Delta, Zhejiang University, Jiaxing 314100, China; The Joint‑Laboratory of Clinical Multi‑Omics Research between Zhejiang University and Ningbo Municipal Hospital of TCM, Ningbo Municipal Hospital of TCM, Ningbo 315010, China; Jinhua Institute of Zhejiang University, Jinhua 321299, China; Corresponding authors at: Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.Type 2 diabetes mellitus (T2DM) is a significant public health issue with high morbidity and mortality. Ginsenoside Rb1 (Rb1) and berberine (BBR), the main bioactive compounds of Panax ginseng and Coptis chinensis, respectively, are known for their hypoglycemic effects. Nevertheless, the synergistic effects and underlying mechanism of Rb1 and BBR on T2DM remain unclear. In this study, we utilized a leptin receptor-deficient (db/db) mouse model to investigate the protective effects of their combination treatment. Our findings demonstrated that the combined use of Rb1 and BBR at a 1:4 ratio had more pronounced effects than the first-line anti-diabetic drug metformin on reducing the weight ratio of white adipose tissue, ameliorating insulin resistance, and improving glucose and lipid metabolism. Using spatial transcriptomics, we revealed that metformin treatment improved gluconeogenesis and lipogenesis only in the periportal zone, while the combination treatment induced improvements throughout the liver lobule, with distinct key targets across different zones, thus underscoring a more comprehensive modulation of hepatic metabolism. This may be the key reason why this combination therapy demonstrated superior protective effects against T2DM. Additionally, the reversed expression of the key callback gene hepcidin (HAMP) and its regulator growth differentiation factor 15 (GDF15) following the combination therapy across all zones, along with validation experiments, further suggested that GDF15/HAMP pathway might be a key mechanism underlying the beneficial effects of Rb1 and BBR against T2DM. This study also indicates a path toward innovative drug cocktails for treating T2DM, offering a holistic approach to regulate the entire liver lobule metabolism.http://www.sciencedirect.com/science/article/pii/S1043661825001367Type 2 diabetes mellitusGinsenoside Rb1BerberineCombination therapySpatial transcriptomics
spellingShingle Rongfang Guo
Shuying Zhang
Anyao Li
Ping Zhang
Xin Peng
Xiaoyan Lu
Xiaohui Fan
Ginsenoside Rb1 and berberine synergistically protect against type 2 diabetes mellitus via GDF15/HAMP pathway throughout the liver lobules: Insights from spatial transcriptomics analysis
Pharmacological Research
Type 2 diabetes mellitus
Ginsenoside Rb1
Berberine
Combination therapy
Spatial transcriptomics
title Ginsenoside Rb1 and berberine synergistically protect against type 2 diabetes mellitus via GDF15/HAMP pathway throughout the liver lobules: Insights from spatial transcriptomics analysis
title_full Ginsenoside Rb1 and berberine synergistically protect against type 2 diabetes mellitus via GDF15/HAMP pathway throughout the liver lobules: Insights from spatial transcriptomics analysis
title_fullStr Ginsenoside Rb1 and berberine synergistically protect against type 2 diabetes mellitus via GDF15/HAMP pathway throughout the liver lobules: Insights from spatial transcriptomics analysis
title_full_unstemmed Ginsenoside Rb1 and berberine synergistically protect against type 2 diabetes mellitus via GDF15/HAMP pathway throughout the liver lobules: Insights from spatial transcriptomics analysis
title_short Ginsenoside Rb1 and berberine synergistically protect against type 2 diabetes mellitus via GDF15/HAMP pathway throughout the liver lobules: Insights from spatial transcriptomics analysis
title_sort ginsenoside rb1 and berberine synergistically protect against type 2 diabetes mellitus via gdf15 hamp pathway throughout the liver lobules insights from spatial transcriptomics analysis
topic Type 2 diabetes mellitus
Ginsenoside Rb1
Berberine
Combination therapy
Spatial transcriptomics
url http://www.sciencedirect.com/science/article/pii/S1043661825001367
work_keys_str_mv AT rongfangguo ginsenosiderb1andberberinesynergisticallyprotectagainsttype2diabetesmellitusviagdf15hamppathwaythroughouttheliverlobulesinsightsfromspatialtranscriptomicsanalysis
AT shuyingzhang ginsenosiderb1andberberinesynergisticallyprotectagainsttype2diabetesmellitusviagdf15hamppathwaythroughouttheliverlobulesinsightsfromspatialtranscriptomicsanalysis
AT anyaoli ginsenosiderb1andberberinesynergisticallyprotectagainsttype2diabetesmellitusviagdf15hamppathwaythroughouttheliverlobulesinsightsfromspatialtranscriptomicsanalysis
AT pingzhang ginsenosiderb1andberberinesynergisticallyprotectagainsttype2diabetesmellitusviagdf15hamppathwaythroughouttheliverlobulesinsightsfromspatialtranscriptomicsanalysis
AT xinpeng ginsenosiderb1andberberinesynergisticallyprotectagainsttype2diabetesmellitusviagdf15hamppathwaythroughouttheliverlobulesinsightsfromspatialtranscriptomicsanalysis
AT xiaoyanlu ginsenosiderb1andberberinesynergisticallyprotectagainsttype2diabetesmellitusviagdf15hamppathwaythroughouttheliverlobulesinsightsfromspatialtranscriptomicsanalysis
AT xiaohuifan ginsenosiderb1andberberinesynergisticallyprotectagainsttype2diabetesmellitusviagdf15hamppathwaythroughouttheliverlobulesinsightsfromspatialtranscriptomicsanalysis